Post-COVID-19 Guillain-Barré Syndrome A case report from Oman

Mohammed M. Al-Zadjali*, Emaad Al Shibli, Mohammed Al Maskari, Arunodaya R. Gujjar, Abdullah Al Asmi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Guillain-Barré syndrome (GBS) has been reported as one of the neurological manifestations linked to COVID-19, a severe acute respiratory syndrome caused by coronavirus 2. We present the case of a 72-year-old male patient attending a tertiary care hospital in Muscat, Oman, in 2020 with a history of progressive bilateral limb weakness and numbness. The current diagnosis was in line with a rare complication of COVID-19. After exclusion of other possible causes, a diagnosis of GBS induced by COVID-19 was made. The patient received 0.4g/kg of intravenous immunoglobulin (IVIG) per day for five days. This case report highlights the characteristics and course of GBS following COVID-19 infection. Further studies are needed to characterize the manifestations and course of various neuromuscular disorders in relation to COVID-19 infection.

Original languageEnglish
Pages (from-to)409-412
Number of pages4
JournalSultan Qaboos University Medical Journal
Volume22
Issue number3
DOIs
Publication statusPublished - Aug 25 2022

Keywords

  • COVID-19
  • Guillain-Barré syndrome
  • IVIG
  • Oman
  • Guillain-Barre Syndrome/diagnosis
  • Immunoglobulins, Intravenous/therapeutic use
  • COVID-19/complications
  • Humans
  • Muscle Weakness
  • Male
  • Aged

ASJC Scopus subject areas

  • General Medicine

Cite this